Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Maya Ilouze"'
Autor:
Anna May Suidan, Laila Roisman, Anna Belilovski Rozenblum, Maya Ilouze, Elizabeth Dudnik, Alona Zer, Nir Peled
Publikováno v:
Journal of Global Oncology, Vol 5, Pp 1-8 (2019)
Externí odkaz:
https://doaj.org/article/96fcb0dd301e42a28b5b9df12f4a28e3
Autor:
Lior Soussan-Gutman, Nir Peled, Smadar Laufer-Geva, R. Grinberg, Anna Belilovski Rozenblum, Richard B. Lanman, Alona Zer, Tal Twito, Elizabeth Dudnik, Ofer Rotem, Laila C. Roisman, Maya Ilouze, Addie Dvir
Publikováno v:
Journal of Thoracic Oncology. 13:1705-1716
Introduction Next-generation sequencing (NGS) of cell-free circulating tumor DNA (cfDNA) enables noninvasive genomic analysis of NSCLC patients. Although plasma-detected genomic alterations (GAs) have been shown to predict targeted therapy response,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73377ea25aea0e4debe66bae3f389a1b
https://doi.org/10.1016/j.jtho.2018.07.101
https://doi.org/10.1016/j.jtho.2018.07.101
Autor:
Maxim Yakimov, Nir Peled, Yosef Landman, Siraj M. Ali, Maya Ilouze, Simon Wein, Rinat Yerushalmi, Victoria Neiman, Nora Ku, Alexa B. Schrock
Publikováno v:
Clinical Breast Cancer. 18:e267-e270
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bde03643948adcdac77c46dca0533478
https://doi.org/10.1016/j.clbc.2017.11.017
https://doi.org/10.1016/j.clbc.2017.11.017
Autor:
Yehiel Elkabetz, Nir Peled, Maya Ilouze, David R. Gandara, Laila C. Roisman, Addie Dvir, Raphael Pfeffer, Richard B. Lanman, B. Miron, Gabi Tarcic, Oded Edelheit, Fabrice Barlesi, Lior Soussan-Gutman
Publikováno v:
Journal of Thoracic Oncology. 12:e81-e84
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f4d148f8948bdd0042799aea9c092af
https://doi.org/10.1016/j.jtho.2017.02.023
https://doi.org/10.1016/j.jtho.2017.02.023
Autor:
S. Geva, Maya Ilouze, Elizabeth Dudnik, Lior Soussan-Gutman, Anna Belilovski Rozenblum, Nir Peled, Addie Dvir
Publikováno v:
Journal of Thoracic Oncology. 12:258-268
Introduction Targeted therapy significantly prolongs survival in lung adenocarcinoma. Current diagnostic guidelines include only EGFR and anaplastic lymphoma receptor tyrosine kinase gene ( ALK ) testing. Next-generation sequencing (NGS) reveals more
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec593690f3c4cfdd2d247032515e0f40
https://doi.org/10.1016/j.jtho.2016.10.021
https://doi.org/10.1016/j.jtho.2016.10.021
Autor:
Elizabeth Dudnik, Maya Ilouze, Anna Belilovski Rozenblum, Alona Zer, Nir Peled, Laila C. Roisman, Anna May Suidan
Publikováno v:
Journal of Global Oncology
Journal of Global Oncology, Vol 5, Pp 1-8 (2019)
Journal of Global Oncology, Vol 5, Pp 1-8 (2019)
Lung cancer (LC) is the leading cause of cancer mortality worldwide. Despite advances in the treatment strategy, including surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapy, 5-year survival is estimated as 9% to 20%.1,2 During
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edeb46a18aaf0014c2e91facc3321585
http://europepmc.org/articles/PMC6550091
http://europepmc.org/articles/PMC6550091
Autor:
Anna Belilovski Rozenblum, Ludmila Fridel, Alona Zer, Ahuva Grubstein, Nir Peled, S. Geva, Elizabeth Dudnik, Laila C. Roisman, Aaron M. Allen, Tzippy Shochat, Elias Bshara, Maya Ilouze, Ofer Rotem
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 124
Efficacy of immune check-point inhibitors (ICPi) in NSCLC with rare targetable drivers (RTDs) is largely unknown.Consecutive patients with NSCLC and RTDs (non-EGFR/ALK, n-82) were selected from the Davidoff Cancer Center database. ORR, PFS, OS with I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2222034ea9e058f84beb64ca122877e0
https://pubmed.ncbi.nlm.nih.gov/30268448
https://pubmed.ncbi.nlm.nih.gov/30268448
Autor:
Anna, Belilovski Rozenblum, Maya, Ilouze, Elizabeth, Dudnik, Lior, Soussan-Gutman, Addie, Dvir, Nir, Peled
Publikováno v:
Harefuah. 156(11)
In the last decade, important advances in understanding the lung cancer cellular signal pathways have led to the designing of targeted drugs that significantly prolong survival. Recent data shows that 64% of lung adenocarcinomas harbor at least one a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2bae9086f257051be021be0be0c84794
https://pubmed.ncbi.nlm.nih.gov/29198084
https://pubmed.ncbi.nlm.nih.gov/29198084
Publikováno v:
Cellular Oncology. 38:247-252
Lung cancer is the leading cause of cancer death. Radiation therapy plays a key role in its treatment. Ionizing radiation induces cell death through chromosomal aberrations, which trigger mitotic catastrophe and apoptosis. However, many lung cancer p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::838dced6d9c460c4e46e64df06f93940
https://doi.org/10.1007/s13402-014-0212-6
https://doi.org/10.1007/s13402-014-0212-6
Autor:
Nir Peled, Hossam Haick, John K. Field, Michael P.A. Davies, Raneen Jeries, Maya Ilouze, Russell Hyde, Michael W. Marcus, Orna Barash
Publikováno v:
British Journal of Cancer
Background: Volatile organic compounds (VOCs) are potential biomarkers for cancer detection in breath, but it is unclear if they reflect specific mutations. To test this, we have compared human bronchial epithelial cell (HBEC) cell lines carrying the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::332274a9904bc9a33b0922784d279a58
https://doi.org/10.1038/bjc.2014.411
https://doi.org/10.1038/bjc.2014.411